Image Place holder

Omar Castaneda Puglianini, MD

Specialty: Medical Oncology
Sub Specialty: Hematology, Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy


Cancer Focus: Multiple Myeloma-Plasma Cell Tumor

Dr. Castaneda Puglianini earned his MD from Universidad Peruana Cayetano Heredia in Lima, Peru, and completed an Internal Medicine residency at Albert Einstein College of Medicine in New York. He completed a Hematology/Oncology fellowship at Virginia Commonwealth University/Massey Cancer Center followed by a Blood and Marrow Transplantation and Cellular Immunotherapy fellowship at Moffitt Cancer Center. Dr. Castaneda Puglianini joins us from Virginia Commonwealth University where he was an Assistant Professor of Medicine and served as Director, CAR T-Cell Therapy Program in the Division of Hematology/Oncology and Palliative Care at VCU Massey Cancer Center. Dr. Castaneda Puglianini’s clinical interests are in the treatment of hematological malignancies with a focus on plasma cell neoplasms using modalities such as autologous and allogeneic hematopoietic stem cell transplantation as well as adoptive cellular immunotherapy. His research areas of interest include prognostic factors associated with progression, the role of minimal residual disease (MRD) and clinical trials investigating novel cellular immunotherapeutic approaches for multiple myeloma and various hematologic malignancies.

Education & Training

Board Certification:

  • Internal Medicine - Hematology
  • Internal Medicine - Medical Oncology


  • Virginia Commonwealth University Massey Cancer Center - Hematology and Oncology
  • H. Lee Moffitt Cancer Center and Research Institute - Blood and Marrow Transplantation


  • Albert Einstein College of Medicine Jacobi Medical Center - Internal Medicine

Medical School:

  • Universidad Peruana Cayetano Heredia Alberto Hurtado School of Medicine - MD
Participating Trials

Open Label, Multi-Center, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: CT053 (); Not Applicable (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Puglianini OC, Peker D, Zhang L, Papadantonakis N. Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management. Lab Med. 2023 Jan.54(1):13-22. Pubmedid: 35960786.
  • Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
  • Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
  • Simmons GL, Castaneda Puglianini O. T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments. Cancers (Basel). 2022 Aug.14(17). Pubmedid: 36077787. Pmcid: PMC9455067.
  • Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, Chow VA, Shadman M, Castaneda Puglianini O, Saucier A, Jacobson CA, Armand P, Simmons G. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021 Sep.5(18):3563-3567. Pubmedid: 34474474. Pmcid: PMC8945592.
  • Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. Drugs Context. 2021 Sep.10. Pubmedid: 34603459. Pmcid: PMC8462994.
  • Simmons GL, Satta T, Castaneda Puglianini O. Clinical experience of CAR T cells for multiple myeloma. Best Pract Res Clin Haematol. 2021 Sep.34(3):101306. Pubmedid: 34625232.
  • Castaneda-Puglianini O, Chavez JC. Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma. J Blood Med. 2021 Aug.12:775-783. Pubmedid: 34466048. Pmcid: PMC8403007.
  • Castaneda Puglianini O, Papadantonakis N. Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts. Ther Adv Hematol. 2020.11. Pubmedid: 32733662. Pmcid: PMC7370557.
  • Castaneda O, Baz R. Multiple Myeloma Genomics - A Concise Review. Acta Med Acad. 2019 Apr.48(1):57-67. Pubmedid: 31264433.
  • Casas J, Castañeda O, Prezza P, Castillo M, Llosa L. [An unusual presentation of liver involvement in hereditary hemorrhagic telangiectasia biliary disease]. Rev Gastroenterol Peru. 2009 Jul.29(3):266-271. Pubmedid: 19898600.

Patient Comments
Overall Satisfaction

35 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments